R. Bilik et al., PREVENTION OF BILIARY-CIRRHOSIS FOLLOWING HEPATIC ARTERIAL THROMBOSISAFTER LIVER-TRANSPLANTATION IN CHILDREN BY USING URSODEOXYCHOLIC ACID, Journal of pediatric surgery, 30(1), 1995, pp. 49-52
Hepatic artery thrombosis (HAT) after liver transplantation is a sever
e complication that often requires retransplantation. The authors have
adopted a different approach, aimed at treating the perioperative HAT
complications aggressively and early, with ursodeoxycholic acid (UDCA
), to try to preserve the original graft. Eighty-six liver transplants
were performed in 73 children (age range, 4.5 months to 17.5 years; m
edian, 2.6 years). HAT occurred eight times, in seven patients (9.3%).
Patients with HAT were significantly younger and smaller (mean age, 0
.8 +/- 0.4 v 4.8 +/- 5.3 years; P < .02; mean weight, 7.4 +/- 0.8 v 18
.7 +/- 16.2 kg; P < .05). The incidence of HAT varied significantly ac
cording to the method of arterial reconstruction used: 4 of 16 (25%) w
hen a donor iliac artery interposition graft to the aorta was used, 4
of 61 (6.6%) when the native hepatic artery was used, and 0 of 9 when
the donor celiac axis was anastomosed directly to the aorta (P < .05).
The incidence of HAT was not significantly different when reduced siz
e grafts were used. Early retransplantation was performed in three of
the eight patients; two survived. All other patients were treated for
4 to 6 weeks with broad-spectrum antibiotics and amphotericin. Five pa
tients were treated with UDCA, three immediately after the acute event
and two after 4 and 6 months (respectively) post-HAT. The patients wh
o had UDCA immediately post-HAT had histologically normal liver biopsy
specimens. Results of liver function tests have been normal. One of t
hese patients required transhepatic stenting of a common bile duct str
icture for several months. For the two patients whose UDCA treatment b
egan 4 or 6 months after HAT, sequential biopsy specimens showed progr
essive evolution of biliary cirrhosis, which led to the need for retra
nsplantation in both patients, 4 and 3.5 years (respectively) after th
e original transplants. The authors believe that early initiation of U
DCA treatment after liver transplantation and HAT may prevent the hepa
totoxic effect of cholestasis and bile salt retention and the accompan
ying biliary cirrhosis. Copyright (C) 1995 by W.B. Saunders Company